Announcements Trials
Browse Landscape

Phase

Phase 1 15Phase 2 11Phase 1/2 10Phase 3 2

Status

Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2

Conditions

Myelodysplastic Syndromes 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myeloid, Acute 2Patient Preference 1

Interventions

Cytarabine 166Cyclophosphamide 110Daunorubicin 88Methotrexate 83Etoposide 66Vincristine 63Mercaptopurine 55Rituximab 54Dexamethasone 54venetoclax 50fludarabine 47Doxorubicin 46Azacitidine 46Idarubicin 45Asparaginase 42Imatinib Mesylate 41Prednisone 39pegaspargase 37Thioguanine 36Radiotherapy 35Mitoxantrone 35Busulfan 31Peripheral Blood Stem Cell Transplantation 25Leucovorin 25Bendamustine Hydrochloride 25fludarabine phosphate 24Filgrastim 24obinutuzumab 23nilotinib 23Granulocyte Colony-Stimulating Factor 23

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × decitabine and cedazuridine drug combination × Other hematologic neoplasm × Clear all
NCT05883956 2025-03-20

PREFER-HMA

Otsuka Australia Pharmaceutical Pty Ltd

Phase 3 Active not recruiting
13 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Patient Preference

NCT03306264 2024-08-27

Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

Astex Pharmaceuticals, Inc.

Phase 3 Completed
227 enrolled 37 charts 1 FDA
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡